IGHE and asthma: Specifically, we evaluate trends over time in clinical control scores (GINA, Composite Asthma Severity Index CASI, exacerbations), lung function, type 2 inflammation markers (fractional exhaled nitric oxide FeNO, total Immunoglobulin E IgE, blood eosinophils), ICS doses, and quality of life.